Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
The combination of low-intensity atorvastatin and ezetimibe was more effective than moderate-intensity atorvastatin single-drug treatment in lowering LDL-C levels and improving other lipid parameters.
MEI005 effectively reduces SMF, offering a safe, minimally invasive option for Chinese adults.
This analysis showed that the real-world benefits and safety of finerenone in patients with CKD and T2D was not modified by baseline diuretic use.
In this post-hoc analysis among patients with acute heart attack, treatment with empagliflozin resulted in a significant beneficial effect on left ventricular end-diastolic and end-systolic volume, without significantly...
These data demonstrate beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity.
Participants on lenacapavir-based regimens demonstrated stability or improvement in HRQoL and other outcomes, with fewer participants reporting bothersome HIV symptoms.
Evinacumab substantially lowered LDL cholesterol levels in patients with HoFH regardless of the degree of LDL receptor function, with low levels sustained over 5 years of follow-up.
While extending inferences from study populations to specific targets can improve the precision of estimates in small subgroups, violating key assumptions creates bias for many subgroups of interest.
In active CD, BAD was prevalent, particularly in isolated ileal disease, and associated with persistent diarrhea, but not endoscopic full symptom relief after treatment.
Patients with resected stage IIB/C melanoma treated with adjuvant nivolumab demonstrated stable HRQoL and minimal bother from side effects.
IC added to CRT does not adversely impact QoL compared to CRT, either during IC, during CRT or later.
In both trial extensions, NPAEs persisted in 3%-4% of participants 96 weeks after switching to a DOR-based regimen, possibly representing the background rate for these events.
These data confirm the benefit of achieving low disease activity states on subsequent radiographic outcomes but did not show a significant impact related to a TC management approach.
PE+topiramate was associated with a greater reduction in PTSD symptoms than PE+placebo during active treatment.
Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms, HRQOL, and work productivity up to 1 year in bDMARD-naïve and TNFi-IR patients with active PsA.
There was a modest relative reduction in infant SSTIs but this was small in absolute terms with no statistically discernible difference.
Our investigations demonstrate that the predictiveness curve extended by these new interpretations of areas provides a comprehensive evaluation of markers or sets of markers for prediction.
The trial vaccine administered following both Essen regimen and Zagreb regimen shows good safety, immunogenicity and immune persistence, and the trial vaccine is not inferior to the control vaccine.
This study provides HRQoL values in a French cohort of CLL patients in consolidation treatment.
Real-world benefits and safety of tildrakizumab for the treatment of scalp psoriasis are sustained long-term.
Implementation of a multi-institutional protocol with the strategy of interval-compressed induction for ES in South America was feasible with favorable results.
This study demonstrated that the FDC of DAPA + GLIM + MET ER tablets once daily was significantly better than dual FDC in achieving glycaemic control in patients with poorly controlled T2DM.
We assessed factors that could predict outcomes after docetaxel chemotherapy in patients with advanced prostate cancer.
Sham-treated eyes with ORT at baseline had less loss of BCVA over 24 months than eyes without ORT.
In this post hoc analysis, GI AEs appeared to contribute slightly to the weight reduction seen with tirzepatide in participants with obesity or overweight with or without T2D.
Best-corrected visual acuity and GA area at baseline did not correlate with BCVA loss, but faster GA growth rates appeared to be associated with faster BCVA loss.
Improvements in objective response rate and PFS for L + P versus sunitinib in aRCC were observed consistently across a range of biomarker subgroups defined using RCC driver mutations, PD-L1, gene expression signatures, and...
Glepaglutide treatment in patients with SBS with intestinal failure resulted in clinically relevant reductions in PS requirements and was well tolerated.
We observed similar efficacy of mesalazine in adult and older adult UC patients.
Asthma-related outcomes occurred less frequently among children who received motavizumab compared with placebo in infancy; however, these findings were not statistically significant, related to insufficient study power.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
